HUTCHMED (China) Limited (HMDCF) Research

HUTCHMED (China) Ltd. operates as a holding company, specializing in the research, development, manufacturing, and sales of both pharmaceutical products and health-focused consumer goods. The company's operations are divided into two main segments: Oncology/Immunology and Other Ventures. The Oncology/Immunology division is dedicated to the discovery, development, and commercialization of targeted therapies and immunotherapies aimed at treating cancer and immunological diseases. In contrast, the Other Ventures segment handles the company's other commercial activities, which include the marketing, production, and distribution of prescription medications and general healthcare products. Established on December 18, 2000, the company maintains its headquarters in Hong Kong.

Market snapshot

Symbol
HMDCF
Price
$2.16
Day change
0.00%
Market cap
$1.8B
P/E ratio
3.86x
52-week range
2.16-3.815
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 1 month

Peer companies

  • Aspen Pharmacare Holdings Limited (APNHF)
  • Aspen Pharmacare Holdings Limited (APNHY)
  • China Medical System Holdings Limited (CHSYF)
  • Curaleaf Holdings, Inc. (CURLF)
  • Dermapharm Holding SE (DMPHF)
  • Haw Par Corporation Limited (HAWPY)
  • Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
  • Hypera S.A. (HYPMY)

Open HUTCHMED (China) Limited (HMDCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.